Last updated 2026-06-18
- Raised $80M funding round, Jul 2024
- Raised $30M funding round led by Pfizer, Oct 2022
- Raised $8.4M funding round led by OurCrowd, Jun 2021
Total raised
$132.0M
Last: 2024-07
Stage
Series C
Founded
2016
Headcount
124
HQ
-, Israel
Sector
Health Tech & Life Sciences
About
CytoReason is a technology company developing a computational model of the human body that simulates human disease on a cellular level, minimizes the need for animal trials, and makes human trials more focused and accurate.
With CytoReason's proprietary database and AI-led platform, pharmaceutical and biotechnology companies can make data-driven decisions quickly and cost effectively. To date, five of the world’s top ten pharma companies use CytoReason’s technology to identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval.
Funding history · 6 rounds · $132.0M total
2024-07
2024-05
Undisclosed
2021-06
$8.4M
2020-07
$10.8M
2020-01
Q&A
- What is CytoReason's primary focus?
- CytoReason is a technology company that develops a computational model of the human body to simulate human disease at a cellular level, aiming to reduce the need for animal trials and enhance the accuracy of human trials.
- When was CytoReason founded?
- CytoReason was founded in September 2016.
- How much funding has CytoReason raised in total?
- CytoReason has raised a total of $132,004,672 in funding.
- Which investors participated in CytoReason's July 2024 funding round?
- In July 2024, CytoReason raised $80,000,000 from investors including Nvidia and Pfizer.
- What is CytoReason's employee count?
- CytoReason has 51–200 employees.
- Who are the co-founders of CytoReason?
- The co-founders of CytoReason include Prof. Shai Shen-Orr, Elina Starosvetsky, and David Harel.
- What is CytoReason's current funding stage?
- CytoReason is currently in its Series C funding stage.
- What technologies does CytoReason utilize?
- CytoReason utilizes Artificial Intelligence, Machine Learning, Biologicals, and Cells in its technology.
- Which investor has consistently participated in multiple funding rounds for CytoReason?
- OurCrowd has participated in multiple funding rounds for CytoReason, including those in July 2020, June 2021, October 2022, May 2024, and July 2024.
Team · 6
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareMedical Decision Support
Technologies
BiologicalsCellsArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProvidersLaboratories
Business model
B2B
Highlights
Verified
Tags
clinical-trialslaboratoriesartificial-intelligencehealthcare-providerspatent-pendingdrug-discoveryclinical-dataclinicsmedical-technologiesdata-analyticsdigital-healthcarebig-datapharma-companiescancermachine-learningbiotechnologybiopharmaceuticalimmunotherapyimmunologybioinformaticsmhealthautoimmune-diseasesmolecular-biologydecision-supportnatural-language-processingcells
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | cytoreason.com |
|---|---|
| linkedin.com/company/12901361 | |
| YouTube | youtube.com/channel/UC7ys04qK-C1M83XTV3NbI6g |
Identifiers & details
| Founded | 2016-9 |
|---|---|
| Employees (exact) | 124 |
Radar intelligence
Publications (Crossref)
| Works | 6 |
|---|
GitHub
| Top repos | stress-load-testing-framework, langfuse, internal-apps-front, nf-amazon, streamlit-cyto |
|---|
Web history (Wayback)
| Domain | cytoreason.com |
|---|